IN THE SUPREME COURT OF THE STATE OF DELAWARE
ZELDA SHEPPARD, §
§ No. 346, 2021
Appellant Below, Appellant §
§ Court Below: Superior Court
v. § of the State of Delaware
§
ALLEN FAMILY FOODS, § C.A. No. S20A-07-001
§
Appellee Below, Appellee. §
Submitted: April 27, 2022
Decided: June 23, 2022
Before VALIHURA, VAUGHN, and TRAYNOR, Justices.
Upon appeal from the Superior Court. AFFIRMED.
Walt F. Schmittinger, Esquire, Gary E. Junge, Esquire, Schmittinger & Rodriguez, P.A.,
Dover, Delaware for Appellant.
John W. Morgan, Esquire, Heckler & Frabizzio, Wilmington, Delaware for Appellee.
VALIHURA, Justice:
This is an appeal of a September 29, 2021 decision by the Superior Court affirming
a decision by the Industrial Accident Board (“IAB” or “Board”) granting Allen Family
Foods’ (“Employer”) Petition for Review (“Petition”). The IAB determined that Zelda
Sheppard’s (“Sheppard”) prescribed narcotic pain medications were no longer
compensable. Sheppard sought to dismiss the Petition at the conclusion of Employer’s
case-in-chief during the IAB hearing, arguing that the matter should have been considered
under the utilization review process. After hearing the case on the merits, the IAB
disagreed, holding that Employer no longer needed to compensate Sheppard for her
medical expenses after a two-month weaning period from the narcotic pain medications.
The Superior Court affirmed.1
Sheppard raises one issue on appeal. She argues that the IAB erred as a matter of
law when it denied Sheppard’s Motion to Dismiss Employer’s Petition because Employer
failed to articulate a good faith change in condition or circumstance relating to the causal
relationship of Sheppard’s treatment to the work injury. Accordingly, Sheppard argues
that the Employer was required to proceed with the utilization review process before
seeking termination of her benefits.
For the reasons set forth below, we AFFIRM the decision of the Superior Court.
1
Opening Br. Ex. B (Sheppard v. Allen Fam. Foods, No. 1373143 (Del. I.A.B. May 11, 2022))
[hereinafter IAB Decision].
2
I. RELEVANT FACTS AND PROCEDURAL BACKGROUND2
A. Sheppard’s Initial Injury
On April 4, 2011, Sheppard slipped and fell on Employer’s cafeteria floor, injuring
her neck, low back, left arm, and left leg (the “Accident”).3 According to Sheppard, she
has sought medical treatment with various providers since the Accident for continuing
problems with her neck, back, left arm, and left leg.4 Following the Accident, Sheppard
received total disability benefits.5
Sheppard was prescribed both opiate and non-opiate medications following the
Accident. She stated that these medications helped with her symptoms, but because they
were not long-acting, she “still need[ed] medication for break-through pain.”6
2
A few references are made to two other IAB decisions involving Sheppard’s Accident, including
Sheppard’s Petition to Determine Additional Compensation Due and Employer’s 2016 Utilization
Review. See Sheppard v. Allen Fam. Foods, No. 1373143 (Del. I.A.B. June 30, 2014) [hereinafter
Sheppard Decision 2014]; Sheppard v. Allen Fam. Foods, No. 1373143 (Del. I.A.B. Aug. 1, 2017)
[hereinafter Sheppard UR Appeal 2017]. Both decisions are included in Sheppard’s Amended
Compendium of Unreported Cases to Appellant’s Amended Opening Brief on Appeal.
3
I.A.B. Decision at 12. The IAB noted the following complaints Sheppard had after her injury:
“complaints of diffuse pain in [her] neck, low back, left shoulder, both hips, and left leg.” Id. at
3.
4
Sheppard initially sought medical treatment at Beebe Health Care with Dr. Green; however,
Sheppard’s doctor has changed a few times since then. After Dr. Green, Sheppard treated with
Dr. Eva Dickinson, and then with Dr. Gala at Alpha Care Medical in 2017. At some point,
Sheppard stopped treating with a doctor and instead was treated by a nurse practitioner, Ms.
Patricia M. Grady. Id. at 12. The full names of some of Sheppard’s treating doctors are not
provided in the record.
5
A009 (I.A.B. Hr’g Tr. at 4).
6
I.A.B. Decision at 12.
3
B. Sheppard’s Petition to Determine Additional Compensation Due
On August 31, 2012, Sheppard filed a Petition to Determine Additional
Compensation Due alleging that she had suffered permanent impairment as a result of her
work related injuries.7 Specifically, Sheppard sought “10% impairment to the cervical
spine, 10% impairment to the lumbar spine and 7% impairment to the right upper
extremity.”8 On July 2, 2014, the IAB ruled that Sheppard had proved that her injuries
resulted in a permanent impairment and that Employer was required to pay benefits for
“10% impairment to the cervical spine and 7% impairment to the right upper extremity[.]”9
C. Employer’s 2016 Utilization Review and Sheppard’s Appeal
In 2016, Employer requested review of “the 8/29/19 and ongoing health care
treatment/service for medications prescribed by Dr. Eva Dickinson” (“Dr. Dickinson”).10
In order to challenge the treatment/service rendered by Dr. Dickinson, Employer pursued
7
Sheppard Decision 2014, No. 1373143, at 2.
8
Id.
9
Id. at 20. The IAB found, however, that Sheppard had not satisfied her burden to prove by
substantial evidence that she had a permanent impairment to the lumbar spine. Id. at 18.
10
A088 (Notice of Non-Certification for Utilization Review at 2). The Employer’s initial request
for Utilization Review in connection with Dr. Dickinson is not in the record before this Court. It
also appears that the reference to the 8/29/19 review is a typo, and should be 8/29/16, given that
the date of the notice is September 19, 2016.
4
utilization review pursuant to 19 Del. C. § 2322F(j)11 and Administrative Regulation 5.0.12
The details of Employer’s request are not in the record; however, the utilization reviewer’s
decision is.13 After two unsuccessful attempts at contacting Dr. Dickinson, the utilization
reviewer determined that certain opioid medications prescribed to Sheppard by Dr.
Dickinson were not compliant with the Delaware Guidelines.14
11
Section 2322F deals with billing and payment for health-care services, and subsection j deals
with utilization review. In pertinent part, subsection j provides that:
[t]he intended purpose of utilization review services shall be the prompt resolution
of issues related to treatment and/or compliance with the health-care payment
system or practice guidelines for those claims which have been acknowledged to
be compensable. An employer or insurance carrier may engage in utilization
review to evaluate the quality, reasonableness and/or necessity of proposed or
provided health-care services for acknowledged compensable claims.
19 Del. C. § 2322F(j).
12
Title 19, Section 1341-5.0, of the Delaware Administrative Code describes the Utilization
Review. See 19 Del. Admin. C. § 1341-5.0
https://regulations.delaware.gov/AdminCode/title19/1000/1300/1340/1341.shtml (last visited
Feb. 22, 2022).
13
A087–88 (Notice of Non-Certification for Utilization).
14
The reviewer certified that the treatment/services provided by Dr. Dickinson “d[id] not comply
with the Delaware HCPS practice guidelines.” A087 (Notice of Non-Certification for Utilization).
Specifically, the reviewer stated that:
Per the DE Guidelines, narcotic medications should be prescribed with strict time,
quantity, duration and definitive cessation parameters. Pain is subjective in nature
and should be evaluated using a scale to rate effectiveness of the narcotic
prescribed.
From the medical records received, there was no documentation of definitive
cessation parameters. There was also no documentation of evaluation of pain by
[Sheppard] based on a pain scale. More so, more than two opioid medications were
prescribed. Apart from the designated short-acting opioid; oxycodone, and long-
acting-opioid; hydromorphone, fentanyl and SUBSYS were also prescribed.
There was no documentation of a second opinion for the use of more than two
opioids from a specialist, as strongly recommended by the Delaware Guidelines.
5
Sheppard appealed the utilization reviewer’s decision to the IAB requesting that the
“Department of Labor emplead Dr. Dickinson in connection with the Utilization Review
of her treatment in this case.”15 According to the IAB decision, the “Department issued
the required notice to Dr. Dickinson of the scheduled hearing[;]” however, Dr. Dickinson
did not appear for the hearing as scheduled.16
On August 1, 2017, the IAB affirmed the decision of the utilization reviewer and
found that “Dr. Dickinson [] failed to substantiate the reasonableness and necessity of her
treatment of [Sheppard] in relation to the [Accident].”17 As a result of the utilization
reviewer’s decision, neither Employer, Employer’s insurance carrier, nor Sheppard, would
“have any liability or responsibility to Dr. Dickinson or her medical practice (nor any
successor entity) for those medical expenses that were subject to the 9/19/2016 Utilization
Review decision.”18 The IAB also stated that “any future treatment with any other provider
may be subject to the Utilization Review process at the carrier’s discretion and option, and
in accordance with the Workers’ Compensation Act and regulations.19
With these, the use of Fentanyl DIS 25 mcg/hr and Subsys 1200 mcg, oxycodone
10 mg, and hydromorphone 32 mg 08/29/16 onward does not comply with the
Delaware Guidelines.
A088 (Notice of Non-Certification for Utilization).
15
Sheppard UR Appeal 2017, No. 1373143, at 1.
16
Id.
17
Id. at 1–2. The IAB noted that the utilization review decision dated September 29, 2016, was
applicable to the treatment of Dr. Eva Dickinson only, and had no bearing on subsequent treatment
obtained by Sheppard from other providers. Id. at 2.
18
Id.
19
Id.
6
D. Employer’s 2019 Petition for Review
On December 2, 2019, Employer filed the Petition pursuant to 19 Del. C. § 2347
seeking to terminate the compensability of Sheppard’s narcotic medications and injection
treatment.20 Employer argued that Sheppard’s “narcotic pain medications are
unreasonable, unnecessary, and unrelated to the industrial accident[.]”21 The parties
stipulated to proceeding before the IAB hearing officer, and the hearing commenced on
June 8, 2020.22
1. Employer’s Case-in-Chief
Employer presented one witness by deposition, namely, Jason Brokaw, M.D. (“Dr.
Brokaw”).23 Dr. Brokaw is a board-certified physical medicine, rehabilitation, and pain
management doctor, and he is a certified provider under the Delaware Workers’
Compensation system.24 Dr. Brokaw reviewed Sheppard’s medical records and examined
Sheppard on three separate occasions: January 5, 2017, September 4, 2019, and February
27, 2020.25
20
Although the Petition for Review mentioned terminating Sheppard’s injection treatment, there
was no testimony or argument presented regarding Sheppard’s injections, and therefore the IAB
did not address or rule on the injections. See I.A.B. Decision at 13 n.2.
21
Id. at 2.
22
Id. at 2. The hearing was held by a Workers’ Compensation Hearing Officer in accordance with
19 Del. C. § 2301B(a)(4).
23
The I.A.B. decision incorrectly identifies Jason Brokaw, M.D., as testifying on behalf of
Sheppard. See I.A.B. Decision at 3.
24
B58–59 (Dr. Brokaw Dep. at 5–6).
25
I.A.B. Decision at 3.
7
Regarding the visit that occurred on September 4, 2019, Sheppard stated that she
was treating with Dr. Gala at Alpha Care Medical when he took over Dr. Dickinson’s
practice. Under Dr. Gala’s care, Sheppard’s medications included a Butrans patch,
oxycodone, and cyclobenzaprine. Sheppard denied any history of illegal drug use, alcohol
abuse, or other problems. Dr. Brokaw asked specifically about any marijuana use, but
Sheppard denied using it. She also indicated that all her urine drug screens had been
compliant. Contrary to Sheppard’s answers to Dr. Brokaw’s questions regarding marijuana
use, “a vast majority of her urine drug screen tests were positive for marijuana from 2011
through 2019.”26
Dr. Brokaw conducted a physical examination which revealed mild pain behavior.
According to Dr. Brokaw, Sheppard had “self-limited range of motion of the cervical spine
with complaints of pain, especially throughout the left neck and trapezius region” as well
as “decreased range of motion of the left shoulder . . . weakness in the left shoulder[,] and
she resisted attempts of passive range of motion, indicating nonphysiologic overlay.”27 He
noted that Sheppard had a Butrans patch on her lumbar spine, and that the patch was not in
the correct location.28 According to Dr. Brokaw, a Butrans patch “is an opiate and has
opioid risks[,]” and therefore the location of the patch is important because the medication
is “absorbed and goes through the entire body[.]”29 He testified that Butrans patch users
26
Id.
27
Id. at 3–4; see B64 (Dr. Brokaw Dep. at 11).
28
I.A.B. Decision at 4.
29
Id.; see B66 (Dr. Brokaw Dep. at 13).
8
are instructed to use the patch in certain locations, and finding the Butrans patch on
Sheppard’s lumbar spine indicated that she either “was not appropriately instructed in its
use or was using it incorrectly.”30
Based on Sheppard’s physical examination and Dr. Brokaw’s review of her record
at the 2019 visit, Dr. Brokaw made the following assessments: there was a disproportionate
description of pain relative to the nature of Sheppard’s accident, Sheppard had ongoing
high dose opiate medications,31 and Sheppard was noncompliant “because she had not told
the truth about her marijuana use to Dr. Brokaw or the treating providers.”32 Accordingly,
Dr. Brokaw “recommended a complete detoxification from any abusable medications
include opiates, benzodiazepines, Soma, and marijuana[.]”33 In order to avoid abrupt
withdrawal, he recommended reducing Sheppard’s medications over the course of three-
months, and then continuing treatment with “non-opioid medication management and
occasional rounds of physical therapy.”34
At the examination on February 27, 2020, Sheppard reported to Dr. Brokaw that she
continued to receive her medications from Alpha Care Medical, but that she was no longer
30
I.A.B. Decision at 4; see B66 (Dr. Brokaw Dep. at 13). According to Dr. Brokaw, “[t]he patient
is instructed to use the Butrans patch around the shoulder girdle, the front of the shoulder, back of
the shoulder, font of the chest, and back of the chest, by alternating the locations.” I.A.B. Decision
at 4.
31
See B67 (Dr. Brokaw Dep. at 14). The opiate medications equated to a range of “ninety to one
hundred milligrams of morphine equivalent [] per day with the combination of Butrans and
oxycodone[.]” I.A.B. Decision at 4.
32
I.A.B. Decision at 5.
33
Id.; see B68 (Dr. Brokaw Dep. at 15).
34
I.A.B. Decision at 5; see B69 (Dr. Brokaw Dep. at 16).
9
receiving treatment from Dr. Gala. Instead, Sheppard reported that she was receiving
treatment from the nurse practitioner.35 Sheppard’s medications at this time included
oxycodone, cyclobenzaprine, and ibuprofen.36 During this examination, Sheppard
admitted to Dr. Brokaw that she used marijuana illegally (i.e., without a medical marijuana
card), but that she was in the process of applying for a card.37 According to Dr. Brokaw,
Sheppard told her treatment providers that she already had a prescription card for medical
marijuana, but the providers never confirmed that assertion.38
Dr. Brokaw’s 2020 examination of Sheppard was similar to the prior one, with
Sheppard having limited range of motion and pain complaints, with the exception that at
this visit Sheppard smelled of marijuana.39 Dr. Brokaw stated that although he believed
medical marijuana to be useful in certain circumstances, in his opinion, it “would not be
35
B70 (Dr. Brokaw Dep. at 17). According to Dr. Brokaw, Sheppard told him that “there were no
actual physicians at Alpha anymore[,]” and Dr. Brokaw stated Sheppard’s statement was
“corroborated by the card that she showed [him] with only nurse practitioners’ names.” Id.
36
I.A.B. Decision at 5. Sheppard reported that the Butrans patch had been stopped but “she was
not really sure why.” Id.; see B70–71 (Dr. Brokaw Dep. at 17–18).
37
B70 (Dr. Brokaw Dep. at 17).
38
See I.A.B. Decision at 5–6; B74 (Dr. Brokaw Dep. at 21). According to Dr. Brokaw:
Ms. Sheppard had told the providers at Alpha Care Medical that she had a medical
marijuana certification card. If you go through all of the treatment records from
Alpha Medical Care, back in 2017 she told them that she was interested in it through
them. Although there is no documentation that they ever provided a medical
marijuana certification.
Overall it is clear that she was using marijuana for many years before this and that
they had never certified her or for that matter made a copy or any other
documentation showing that she actually had a medical marijuana certification.
B74–75 (Dr. Brokaw Dep. at 21–22).
39
I.A.B. Decision at 5; B73 (Dr. Brokaw Dep. at 20).
10
appropriate for [Sheppard].”40 He further testified that he “cannot causally relate a need
for the ongoing treatment to [Sheppard’s] industrial injury in April 2011, because her
objective findings do not correlate to her subjective symptoms.”41 Dr. Brokaw testified as
follows:
Q. Okay. So she has muscular pain, she has neuropathic pain also; is that
fair to say?
A. I suppose so because of her description of her symptoms. You may also
see in my previous reports that I cannot causally relate for a need for ongoing
treatment to the work injury of April of 2011 because her objective findings
do not correlate to her subjective symptoms.42
....
I in general also wanted to provide some form of conservative care treatment
that would benefit her so that we’re not just cutting her off from all treatment.
But, once again, Ms. Sheppard has an issue with not telling the truth and
credibility.
So I’m really not sure how much of the pain that she describes to me or her
treating providers is genuine versus when you discuss musculoskeletal versus
neuropathic. And I certainly don’t correlate the need for ongoing treatment
to the work injury of April 2011.43
....
So, yes, I would correlate her need for any treatment to other problems,
whether it’s preexisting disease, subsequent disease or psychiatric disease.44
40
B82 (Dr. Brokaw Dep. at 29); see I.A.B. Decision at 6–7.
41
I.A.B. Decision at 7; see B88–89 (Dr. Brokaw Dep. at 35–36). According to Dr. Brokaw,
Sheppard had “subjective symptoms that sound like neuropathic pain, such as the pain shooting
up and down her left leg, but [Sheppard] has a credibility issue with not telling the truth, so Dr.
Brokaw does not know how much of the pain she describes is genuine.” I.A.B. Decision at 7.
42
B87–88 (Dr. Brokaw Dep. at 34–35).
43
B88–89 (Dr. Brokaw Dep. at 35–36).
44
B89 (Dr. Brokaw Dep. at 36).
11
At the conclusion of Employer’s case, Sheppard moved to dismiss or, in the
alternative, for a directed verdict.45 She argued that Employer sought to end Sheppard’s
ongoing medical treatment, and therefore, Employer had to submit Sheppard’s treatment
to the utilization review process.46 Sheppard’s motion was taken under advisement, and
the hearing officer deferred her decision until after the case was heard on the merits.47
2. Sheppard’s Case-in-Chief
Sheppard presented one witness by deposition, Patricia Grady, CRNP, (“NP
Grady”) the nurse practitioner who treated Sheppard.48 NP Grady had 19 years of
experience as a nurse practitioner and was licensed in Maryland and Delaware. In
addition, NP Grady was a certified provider under the Delaware Workers’ Compensation
system.49 NP Grady reviewed Sheppard’s history of treatment with Alpha Care Medical.50
She testified that Sheppard was stable and was benefiting from her treatment with narcotic
45
I.A.B Decision at 2; A028 (I.A.B. Hr’g Tr. at 23).
46
A028–30 (Hr’g Tr. at 23–25).
47
Initially, the hearing officer denied the motion to proceed on with the merits of the case. A035
(I.A.B. Hr’g Tr. at 30). However, the hearing officer clarified that she was going to defer her
decision. A036 (I.A.B. Hr’g Tr. at 31).
48
A036 (I.A.B. Hr’g Tr. at 31).
49
A037–38 (I.A.B. Hr’g Tr. at 32–33); B4–5 (NP Grady Dep. at 4–5). According to NP Grady,
nurse practitioners initially train under a physician for approximately 500 hours; however, nurse
practitioners can work independently and are “able to diagnose and treat illnesses.” B5–6 (NP
Grady Dep. at 5–6). In addition, NP Grady’s credentials allow her to prescribe medications, both
controlled substances (narcotics) as well as non-narcotic, non-controlled substances. B7 (NP
Grady Dep. at 7). Employer challenged NP Grady’s credentials, asking the IAB to determine
whether NP Grady qualified as an expert medical witness. A039–40 (I.A.B. Hr’g Tr. at 34–45).
However, the IAB found that “[g]iven Ms. Grady’s credentials as a licensed nurse practitioner who
is a certified provider pursuant to the Delaware workers’ compensation system, [the IAB found]
that she is capable of testifying as an expert medical witness[.]” I.A.B. Decision at 8 n.1.
50
I.A.B. Decision at 8; B10 (NP Grady Dep. at 10); A042 (I.A.B. Hr’g Tr. at 37).
12
pain medication, and that she was a cooperative patient.51 NP Grady disagreed with Dr.
Brokaw’s opinion that Sheppard was not compliant. NP Grady also did not agree that
Sheppard should be discontinued from opiate medication.52 Instead, NP Grady opined that
the narcotic pain medication was reasonable, necessary, and was causally related to the
Accident.53
On cross-examination, NP Grady indicated that her records showed Sheppard had a
medical marijuana card, despite Sheppard’s admission to Dr. Brokaw that she did not have
one at that time.54 NP Grady acknowledged that during Sheppard’s treatment at Alpha
Care Medical facility, there was no evidence of a decrease in the prescribed narcotic pain
medication.55 Rather, as NP Grady testified, Sheppard’s narcotic medication had actually
increased during March 2018.56 In addition, NP Grady testified that Sheppard would be a
“perfect patient” to be weaned off of opiate prescriptions and transitioned to use of the
CBD or THC compounds.57
51
I.A.B Decision at 9; B27 (NP Grady Dep. at 27).
52
B26–27 (NP Grady Dep. at 26–27).
53
I.A.B. Decision at 10–11; B28–29 (NP Grady Dep. at 28–29); B40 (NP Grady Dep. at 40).
54
I.A.B. Decision at 9–11; B32–35 (NP Grady Dep. at 32–35); A049–51 (I.A.B. Hr’g Tr. at 44–
46).
55
I.A.B Decision at 12; B34–35 (NP Grady Dep. at 34–35).
56
I.A.B. Decision at 12.
57
B28 (NP Grady Dep. at 28). Specifically, NP Grady testified as follows:
Q: Okay. In terms of your expectations for the future, Ms. Grady, I assume
given the consistency of what we’ve seen over the last few years, it would
be fair to assume status quo essentially, that this may continue in the same
fashion going forward for the foreseeable future?
13
Sheppard testified on her own behalf. She stated that she had been in continuous
treatment since the Accident in 2011 and had suffered ongoing effects involving her “neck,
back, left arm, and left leg.”58 She testified about her pain medications, occasions when
she had to go without her medication, and how that affected her ability to do basic tasks
around the house.59 Regarding her medical marijuana card, Sheppard clarified that she
obtained a medical marijuana card several weeks prior to the hearing, and that using
marijuana (albeit illegally prior to receiving her card) had helped her.60
E. The IAB Decision
On June 22, 2020, the IAB issued a written decision. The IAB briefly considered
Sheppard’s motion to dismiss and denied it, finding that utilization review was not
A: Yes. Of course, you know, our goal is -- our goal is definitely to lower,
wean off of the opiates for sure, you know, for her to use more of the CBD,
medical marijuana, mindfulness -- those are all things we stress -- cognitive
behavioral health is also very helpful and CBD helps lower opiate reliance
-- it really does. We’ve seen that -- I've seen that firsthand.
Q: Okay. So it sounds as if your plan would be that hopefully reduction in the
opiate prescriptions would be an option as she’s able to make further use of
the CBD or THC compounds?
A: Yes. Absolutely. Transition. That’s where my treatment goal and, you
know, what I see in her future, sure.
Q: Okay. In your view, that would be a safe, or safer treatment plan in the
sense that, you know, any medication is -- no medication is without risk? I
say “safter” in that context -- that would be an improvement for her?
A: Yes. I think it would be much safter for her to wean, and we’ve seen good
success with that, and she’s a perfect patient for that. She would do very
well.
B27–28 (NP Grady Dep. at 27–28).
58
I.A.B. Decision at 12; see A062–63 (I.A.B. Hr’g Tr. at 57–58).
59
I.A.B. Decision at 12–13.
60
I.A.B. Decision at 13; A069–70 (I.A.B. Hr’g Tr. at 64–65).
14
necessary because Employer presented sufficient evidence on the issue of causation.
Specifically, the IAB stated that “there is sufficient evidence that causation is genuinely at
issue, as per [Employer’s] Petition and Dr. Brokaw’s opinion.”61
The IAB then considered the merits of the case and held that Employer “met its
burden of proof regarding the narcotic pain medications.”62 The IAB “accept[ed] Dr.
Brokaw’s opinion over [NP] Grady’s opinions” because the IAB “[found] Dr. Brokaw’s
opinions [were] more persuasive as they [were] consistent with the facts of this case and
[Sheppard’s] condition.”63 Further, the IAB noted that “[NP] Grady was unaware of
[Sheppard’s] illegal use of marijuana for many years” which negatively impacted NP
Grady’s testimony because “she was either ignoring what [was] listed on the urine drug
screen reports and turning a blind eye to it or she was misled by [Sheppard] into believing
[Sheppard] had a valid medical marijuana card.”64
The IAB also found that Sheppard was not credible because she initially denied
using marijuana when asked by Dr. Brokaw.65 Accordingly, the IAB concluded that the
use of narcotics had not led to an improvement in her condition, and, therefore, it agreed
with Dr. Brokaw’s conclusion that Sheppard should be weaned off the narcotics.66
61
I.A.B. Decision at 2.
62
Id. at 13.
63
Id. at 14.
64
Id.
65
Id. at 14–15.
66
Id. at 15.
15
F. Sheppard’s Appeal to the Superior Court
Sheppard appealed to the Superior Court, arguing that her motion to dismiss should
have been granted and the matter referred to the utilization review process under 19 Del.
C. § 2322F(h). According to Sheppard, Employer challenged whether her treatment was
reasonable and necessary, and, therefore, was required to submit the treatment in dispute
to utilization review. Further, Sheppard argued that Employer’s Petition, filed pursuant to
19 Del. C. § 2347, required Employer to prove a change in Sheppard’s status. Sheppard
argued that Employer failed to show such a change.
The Superior Court reviewed both Section 2322F(h) and Section 2347. It explained
that when causation is at issue, utilization review is not available because under utilization
review, the employer waives the right to contest causation. Therefore, because Employer
wanted to argue causation, the Superior Court found that it was appropriate for the
Employer to challenge Sheppard’s ongoing treatment by submitting the Petition.
As for the question of whether Sheppard’s medical services were necessary and
reasonable, or whether the expenses incurred were casually related to Sheppard’s Accident,
the court concluded that these were “purely factual issues entirely within the purview of
the Board.”67 Accordingly, adhering to the court’s standard of review, the court affirmed
the IAB’s decision, concluding that the IAB’s decision was “supported by substantial
evidence” and “free from legal error.”68
67
Sheppard v. Allen Fam. Foods, 2021 WL 4453591, at *4 (Del. Super. Sept. 29, 2021).
68
Id.
16
This appeal followed.
II. CONTENTIONS ON APPEAL
On appeal, Sheppard contends that the Board erred in denying her motion to dismiss
because Employer lacked a good faith basis to challenge a change in condition or
circumstance relating to the causal relationship of Sheppard’s treatment following the
Accident. She argues that there can be no such good faith basis because three separate
events “conclusively established causation.”69 First, Sheppard argues that Dr. Brokaw’s
opinion that Sheppard’s Accident-related injuries should have resolved by 2012 is contrary
to the law of the case because in 2014 the IAB found that Sheppard had established
permanent impairments. Second, Sheppard argues that Employer conceded causation
when it submitted to the utilization review process in 2016. Third, Sheppard contends that
Employer conceded causation by continuing to pay for Sheppard’s treatment from the time
of the Accident in 2011 up to September 2019. As a result of these events, Sheppard argues
that Employer had no legitimate factual basis to contest causation.
For the reasons explained below, we reject Sheppard’s challenges.
III. SCOPE AND STANDARD OF REVIEW
“The review of an Industrial Accident Board’s decision is limited to an examination
of the record for errors of law and a determination of whether substantial evidence exists
to support the Board’s findings of fact and conclusions of law.”70 “Substantial evidence is
69
Reply Br. at 6.
70
Powell v. OTAC, Inc., 223 A.3d 864, 870 (Del. 2019) (citing Roos Foods v. Guardado, 152 A.3d
114, 118 (Del. 2016)).
17
‘such relevant evidence as a reasonable mind might accept as adequate to support a
conclusion.’”71 “It is ‘more than a scintilla but less than a preponderance of the
evidence.’”72 “On appeal, this Court will not weigh the evidence, determine questions of
credibility, or make its own factual findings.”73 “In reviewing an appeal from a decision
of the Board, this Court and the Superior Court must both determine whether the Board’s
decision is supported by substantial evidence and is free from legal error.”74 “Weighing
the evidence, determining the credibility of witnesses, and resolving any conflicts in the
testimony are functions reserved exclusively for the Board.”75 “Further, ‘[o]nly when there
is no satisfactory proof to support a factual finding of the Board may the Superior Court or
this Court overturn that finding.’”76
IV. ANALYSIS
Sheppard correctly observes that “[a]lthough [S]ection 2347 allows the Board to
modify an award, it does not allow the Board to retroactively change an award.”77 As this
Court explained in Betts v. Townsends:78
Under 19 Del. C. § 2347, the Board has statutory authority to review a prior
agreement or award ‘on the ground that the incapacity of the injured
employee has subsequently terminated, increased, diminished or recurred or
71
Id. (citing Roos Foods, 152 A.3d at 118).
72
Id. (citing Noel-Liszkiewicz v. La-Z-Boy, 88 A.3d 188, 191 (Del. 2013)).
73
Id. (citing Person-Gaines v. Pepco Holdings, Inc., 981 A.2d 1159, 1161 (Del. 2009)).
74
Id. (citing Noel-Liszkiewicz, 68 A.3d at 191).
75
Id. (citing Noel-Liszkiewicz, 68 A.3d at 191).
76
Id. (citing Noel-Liszkiewicz, 68 A.3d at 191).
77
Opening Br. at 16.
78
765 A.2d 531 (Del. 2000).
18
that the status of the dependent has changed . . . .’ Where the Board is asked
to reconsider the incapacity or status of a claimant based on one of these
specifically delineated changes in circumstances, the doctrine of res judicata
is inapplicable. . . . Res judicata would, however, prevent the Board from
reviewing the correctness of a prior award.79
Thus, when the Board awards compensation, “it is not an adjudication as to the claimant’s
future condition and does not preclude subsequent awards or subsequent modifications of
the original award.”80 “A contrary rule would render § 2347 meaningless.”81
Dr. Brokaw’s opinion is not a bar to the Petition even though he testified that he
“would have expected all of the conditions that [were] casually related to the April 2011
injury to have gone back to preinjury status within a one year time period.”82 Dr. Brokaw
provided expert testimony, given to a reasonable degree of medical certainty, that he
“certainly [did not] correlate the need for ongoing treatment to the work injury of April
79
Id. at 534 (citations omitted).
80
Shively v. Allied Systems Ltd., 2010 WL 537734, at *10 (Del. Super. Feb. 9, 2010) (quoting
A.M. Swarthout, Annotation, Res Judicata as Regards Decisions or Awards Under Workmen’s
Compensation Acts, 122 A.L.R. 550), aff’d 998 A.2d 851, 2010 WL 2651602 (Del. July 1, 2010)
(TABLE).
81
Id. (citing Harris v. Chrysler Corp., 541 A.2d 598, 1988 WL 44783, at *1 (Del. April 8, 1988)
(TABLE) (stating that “the doctrine of res judicata is not a bar to the Board’s exercise of its
authority conferred by 19 Del. C. § 2347 to review, modify or terminate previous awards upon
proof of subsequent change of condition”)).
82
B90 (Dr. Brokaw Dep. at 37). Dr. Brokaw testified as follows during his deposition:
Q: When did it cease to be related to the work injury?
A: Based on her mechanism of injury and the benign nature of her objective
studies I would have expected all of the conditions that are causally related
to the April 2011 injury to have gone back to preinjury status within a one
year time period. As such she may have had appropriate treatment for a
year, i.e., by the beginning of 2012. After that point her subjective
symptoms do not correlate with her objective findings and the causal
relationship is certainly questionable after that time period.
B90–91 (Dr. Brokaw Dep. at 37–38). The parties stipulated to his expert qualifications.
19
2011.”83 However, Employer was not submitting Brokaw’s testimony to reverse or alter
the IAB’s prior decisions or to convince the IAB to retroactively terminate Sheppard’s
treatment or disability benefits.84 Rather, Dr. Brokaw was merely giving his opinion
regarding Sheppard’s current objective findings and her subjective symptoms, and
Employer was not attempting to relitigate the IAB’s determination that Sheppard had a
permanent injury at the time of the IAB hearing in 2014.85
In addition, Employer did not waive its ability to challenge causation in its Petition
because it pursued utilization review in 2016. Utilization review is available for the prompt
resolution of issues related to whether a claimant’s treatment is in compliance with the
health care payment system or practice guidelines for those claims that have been
acknowledged as compensable.86 Further, utilization review may be sought in order to
83
B88–89 (Dr. Brokaw Dep. at 35–36).
84
See e.g., Puckett v. Matrix Servs., 2013 WL 69234, at *2–3 (Del. Jan. 7, 2013) (finding that res
judicata and collateral estoppel did not apply where the Board was not invalidating or revisiting
the correctness of the prior award of temporary total disability benefits where the employee’s
second petition related to the separate issue of permanent partial disability).
85
As Employer points out, “[n]o prior Board Decision exists addressing causation as to current
treatment in the context of [Sheppard’s] illegal marijuana use, evidence of dishonesty, or the
transfer of opioid prescriptions from a medical doctor to a nurse practitioner.” Answering Br. at
19.
86
19 Del. Admin. C. §1341-5.1; see 19 Del. C. § 2322F(h). In full, Section 2322F(h) entitled
Prompt pay required for nonpreauthorized care provides:
An employer or insurance carrier shall be required to pay a health care invoice
within 30 days of receipt of the invoice as long as the claim contains substantially
all the required data elements necessary to adjudicate the invoice, unless the invoice
is contested in good faith. If the contested invoice pertains to an acknowledged
compensable claim and the denial is based upon compliance with the health care
payment system and/or health care practice guidelines, it shall be referred to
utilization review. Any such referral to utilization review shall be made within 15
days of denial. Unpaid invoices shall incur interest at a rate of 1% per month
20
evaluate the quality, reasonableness, and necessity of proposed or provided healthcare
services for acknowledged compensable claims.87 Utilization review is to be utilized when
causation is not at issue.88 This is because the legislature intended to, among other things,
streamline the method of payment of expenses “in cases where the employer does not
dispute, i.e. ‘acknowledges,’ injury.”89
By contrast, an employer’s ability to challenge causation is set forth in Section
2347.90 The plain language of Section 2347 does not prohibit an employer from seeking
review under Section 2347 if the employer previously had sought to evaluate a claimant’s
treatment through the utilization review process. In this case, the utilization review in 2016
specifically challenged Dr. Dickinson’s treatment of Sheppard and whether that treatment
payable to the provider. A provider shall not hold an employee liable for costs
related to nondisputed services for a compensable injury and shall not bill or
attempt to recover from the employee the difference between the provider’s charge
and the amount paid by the employer or insurance carrier on a compensable injury.
19 Del. C. § 2322F(h) (emphasis added).
87
Sheppard, 2021 WL 4453591, at *4. See 19 Del. C. § 2322F(j).
88
See Poole v. State, 77 A.3d 310, 311 (Del. Super. 2012) (noting that utilization review “would
be available to employers and/or insurers for injuries which have been ‘acknowledged’ as
compensable.”).
89
Id. at 320, 323 (referring to the language of Section 2322(F)(j), specifically, that “[t]he intended
purpose of utilization review services shall be the prompt resolution of issues related to treatment
and/or compliance with the health care payment system or practice guidelines for those claims
which have been acknowledged to be compensable”).
90
19 Del. C. § 2347. In pertinent part, Section 2347 provides:
On the application of any party in interest on the ground that the incapacity of the
injured employee has subsequently terminated, increased, diminished or recurred
or that the status of the dependent has changed, the Board may at any time, but not
oftener than once in 6 months, review any agreement or award.
19 Del. C. § 2347.
21
was in compliance with the practice guidelines for Delaware’s Health Care Payment
System for workers’ compensation. The utilization reviewer did not, and could not,
consider whether Sheppard’s condition as of the December 2, 2019 Petition was causally
related to Sheppard’s 2011 Accident. Therefore, the 2016 utilization review does not bar
the Petition.
Finally, Employer’s continued payment for Sheppard’s treatment through
September 4, 2019, does not translate into a waiver of causation with respect to the
December 2019 Petition.91 Permanent impairment awards do not serve as a permanent bar
on challenges to future treatment,92 and thus, Employer’s continued payment of medical
expenses through September 4, 2019, is not a permanent bar to its present Petition.93
Sheppard has framed her challenge primarily as a factual challenge to Employer’s
good faith basis for filing the Petition. Even Sheppard conceded before the Board that she
91
Employer argues that its continued payment for Sheppard’s treatment also does not imply an
agreement but notes that Sheppard “does not cite it as such.” Answering Br. at 16. Employer
notes that Sheppard “did not raise a theory of implied agreement in this matter.” Id. at 17 n.56
(emphasis in original). Our review of the record before us indicates that this theory was not raised
in the proceedings below. Accordingly, it has been waived. Del. Sup. Ct. R. 8.
92
See e.g., Pekala v. E.I. DuPont De Nemours & Co., 2007 WL 1653496, at *1 (Del. Super. May
31, 2007) (affirming the Board’s decision to deny the claimant’s request for additional permanent
impairment benefits based on claimant’s continued medical conditions that were triggered by
exposure to mold after claimant’s employment had terminated); Simmons v. Delaware State Hosp.,
660 A.2d 384, 386 (Del. 1995) (affirming the Board’s decision to terminate claimant’s total
disability benefit payments, and instead award claimant partial disability benefits and permanent
impairment benefits).
93
See e.g., DeShields v. State, 2004 WL 1551453, at *3 (Del. Super. June 15, 2004) (noting that
“[t]he claimant’s argument that the previous finding of a 5% permanent disability requires a
finding in her favor under the doctrine of res judicata must also be rejected,” and stating that “[t]he
fact that a person is once found to have a 5% permanent disability to the low back does not mean
that all future complaints of low back pain or proposed treatment for the low back are related to
the 5% permanent disability”).
22
was “not suggesting that, as a procedural matter, Employers cannot dispute medical
treatment on a causation basis, via a petition for review.”94 Rather, her counsel argued that
“the record of facts here [does] not support the necessary causation dispute, at least not on
good faith, because of the record inconsistencies with the facts in this case.”95
The Board, however, was satisfied as to the good faith basis for the causation
challenge. The record supports that determination as it shows that there is substantial
evidence to support the IAB’s decision. Dr. Brokaw testified as a medical expert and
disputed the causal relationship of Sheppard’s ongoing treatment to her Accident, and he
did so after reviewing her available records and personally examining her. The IAB, as
the factfinder, determined that Dr. Brokaw’s conclusions were more credible than NP
Grady’s, and that Sheppard was incredible. The Employer had new evidence of Sheppard’s
dishonesty with her doctors. For example, she lied about her illegal use of marijuana. She
began receiving her treatment from a nurse practitioner only, and not a medical doctor, and
the nurse practitioner was unaware of Sheppard’s illegal use of marijuana. These facts,
noted by the Board and the Superior Court, suffice to satisfy the good faith obligation
sufficient to withstand Sheppard’s motion to dismiss.
The IAB then properly addressed the merits of the case, and we find that it was not
legally erroneous and that it was supported by substantial evidence, including expert
medical testimony. Therefore, reversal of the Superior Court is not warranted.
94
A034 (I.A.B. Hr’g Tr. at 29).
95
Id.
23
V. CONCLUSION
Based on the foregoing, we hold that the IAB’s decision is supported by substantial
evidence, and therefore the decision of the Superior Court is AFFIRMED.
24